Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Community First Bancshares, Inc. (NASDAQ: CFBI).

Full DD Report for CFBI

You must become a subscriber to view this report.


Recent News from (NASDAQ: CFBI)

Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected by End of Year
Namodenoson seeks to address a major unmet need for Child Pugh B patients with advanced liver cancer Namodenoson has received Fast Track Status in the U.S. and Orphan Drug Designation in Europe and the U.S. Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biote...
Source: Business Wire
Date: September, 04 2018 07:00
Can-Fite BioPharma Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018
Can-Fite BioPharma (CANF), today announced it will be featured as a presenting company at the 20 th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel...
Source: Business Wire
Date: August, 29 2018 07:00
Can-Fite Announces Enrollment of First Patient in its Comfort(TM) Phase III Trial of Piclidenoson in Psoriasis
Study initiation will prompt a milestone payment from the recently signed deal with Gebro Holding Psoriasis Therapeutic Market is Estimated to Reach $11.4B in 2020 Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of pr...
Source: Business Wire
Date: August, 21 2018 07:00
Can-Fite Receives from CMS Medical Venture Investment Limited $2,000,000 Upfront Payment as Part of Development, Registration and Marketing Agreement for Piclidenoson and Namodenoson in China
Additional milestone and sales payments total up to $72.5M plus double-digit royalties Recently signed CMS agreement adds to four existing distribution agreements in Canada, South Korea and three countries in Europe (Spain, Switzerland and Austria) Can-Fite BioPharma Ltd . (...
Source: Business Wire
Date: August, 07 2018 09:14
Can-Fite Signs Multi-Million Dollar Development and Distribution Agreement for Piclidenoson and Namodenoson in China with CMS Medical
Upfront and milestone payments total up to $74.5M plus double-digit royalties CMS will be responsible for the development, registration and marketing of the drugs in China Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipelin...
Source: Business Wire
Date: August, 06 2018 05:54
Can-Fite Granted Australian and Chinese Patents for Erectile Dysfunction Drug
Erectile dysfunction market is estimated to reach $3.2 billion by 2022 Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunctio...
Source: Business Wire
Date: July, 17 2018 07:00
Drugs with Mechanism of Action Utilized by Namodenoson Are Recommended by Leading U.S. Researchers to Be Developed to Combat Liver Cancer
A third party validation for the Can-Fite scientific approach to combat Liver Cancer ( https://www.dovepress.com/article_39060.t87482447 ) A Phase II study in patients with advanced liver cancer (hepatocellular carcinoma) is currently ongoing with Namodenoson and completed pat...
Source: Business Wire
Date: July, 02 2018 07:00
Can-Fite Updates on Status of Phase II Advanced Liver Cancer Trial
Accumulated safety data to date continues to indicate a favorable drug safety profile without hepatotoxicity Namodenoson has an Orphan Drug Designation in Europe and the U.S., as well as Fast Track Status in the U.S. Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI...
Source: Business Wire
Date: June, 19 2018 07:00
Can-Fite Reports on New Pre-Clinical Developments with Its NASH Drug Namodenoson
Robust anti-NASH effects when drug is administered orally Data support the selection of the primary endpoint for the ongoing Phase II study Enrollment for the Phase II study is expected to be completed end of 2018; data release expected in H1/2019 Can-Fite BioPharm...
Source: Business Wire
Date: June, 11 2018 07:00
Can-Fite Reports First Quarter 2018 Financial Results and Provides Clinical Update
- Company Received upfront payment of $2.2M as Part of Distribution Agreement for Piclidenoson in 3 European Countries - Namodenoson Phase II Liver Cancer, Phase II NAFLD/NASH and Phase III Rheumatoid Arthritis studies are Ongoing Can-Fite BioPharma Ltd . (NYSE American: ...
Source: Business Wire
Date: June, 01 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0811.3511.564611.564611.305,096
2018-05-1711.2511.2611.2711.15016,204

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-131001,7705.6497Cover
2018-12-1020050040.0000Short
2018-12-073002,42612.3660Cover
2018-12-061002,1404.6729Cover
2018-12-045181,56233.1626Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CFBI.


About Community First Bancshares, Inc. (NASDAQ: CFBI)

Logo for Community First Bancshares, Inc. (NASDAQ: CFBI)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: CFBI)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 02 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 27 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: February, 12 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: January, 23 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: December, 26 2017
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: November, 02 2017

       

       


      Daily Technical Chart for (NASDAQ: CFBI)

      Daily Technical Chart for (NASDAQ: CFBI)


      Stay tuned for daily updates and more on (NASDAQ: CFBI)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: CFBI)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CFBI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CFBI and does not buy, sell, or trade any shares of CFBI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/